For example, in a recent basket study evaluating the efficacy of a pan-HER inhibition (neratinib) in refractory tumors harboring activating mutations in HER2/3, neratinib activity was influenced by both tumor lineage and mutation type (74). The gene discussed is ERBB2; the disease is neoplasm.